Newsletter Subject

Daily Headlines: Hemiplegic Migraine Tied to Depression

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Mon, Nov 14, 2016 12:04 PM

Email Preheader Text

Daily Headlines November 14, 2016 [Non-Small Cell Lung Cancer @POC |Grant] [Multiple Myeloma @POC|Gr

Daily Headlines November 14, 2016 [Hemiplegic Migraine Tied to Depression] [AS: Is Xeljanz the Next Big Thing?] CME/CE [Brain Implant Helps Locked-In Patient Communicate] CME/CE [D.C. Week: Obamacare Days Appear Numbered] [Two Years of Immunotherapy Falls Short in Hay Fever] CME/CE Additional Resources [Diagnosis and Treatment of Relapsed Myeloma] [AML: Beware of Pre-leukemic Clones Surviving Chemotherapy] [Boosting Lung Cancer Outcomes in Diabetics] Industry Resources [Site For Endocrinologists Low Testosterone Due To Certain Medical Conditions. Treatment Info.] [T2D Treatment Information HCPs - Learn About A Treatment For Adults With Type 2 Diabetes Today.] [Myelomatosis A Treatment Option For Previously Treated Multiple Myeloma. HCP Site.] Recent Headlines [ECTRIMS: Contrasting Popular MS Oral Drugs] CME/CE [What to Do When Pressured to Behave Badly] ['It Would Be Great If I Was Pushed Out of Business': What We Heard This Week] [What Do We Know About Kids Who Rapidly Get Fatter?] [Cedars-Sinai Testing Virtual Reality for Pain Management] ADVERTISEMENT This Week's Survey [Could MACRA Be Worse than SGR?] [Physicians finally succeeded in getting rid of the hated][SGR system for Medicare payments], with [MACRA] as the replacement. But now many docs are [complaining that MACRA is a bad deal] too. CME Spotlights [Chronic Lymphocytic Leukemia w/ Watson @POC] [Source: @Point of Care] [Non-Small Cell Lung Cancer (NSCLC) @POC (WATSON)|Grant] [Source: @Point of Care] [Clinical Context: Multiple Myeloma] [Source: Projects in Knowledge, Inc.] [Multiple Myeloma (MM) @POC|Grant|App] [Get Multiple Myeloma @Point of Care, support platform for multiple myeloma diagnosis, treatment & managementrnSource: @Point of Care] [Prostate Cancer @POC] [Source: @Point of Care] [Managing the Patient with Metastatic Melanoma: A Comprehensive, Evidence-Based Approach] [Source: Robert Michael Educational Institute LLC (RMEI)] [Immuno Oncology] [Source: @Point of Care] [Clinical Convergenceu2120: Patient and Provider Perspectives in NSCLC: Initial Visits] [Source: Robert Michael Educational Institute LLC (RMEI)] [Clinical Convergenceu2120: Patient and Provider Perspectives in NSCLC: Follow-up Visits] [Source: Robert Michael Educational Institute LLC (RMEI)] [Biosimilars--Can you explain extrapolation? Interchangeability? Substitution?] [Source: France Foundation] [Playing The Offense In Advanced Basal Cell Carcinoma: A Team Approach To Treatment And Management] [Source: RMEI] [MDS and Acute Myeloid Leukemia (MDS and AML) @POC] [Source: Projects in Knowledge, Inc.] [Skin Cancers@Point of Care] [Source: @Point of Care] [Gynecologic Cancers @POC] [Source: @Point of Care] [Clinical Context: Prostate Cancer] [Source: Projects in Knowledge, Inc.] [Breast Cancer@POC w/Watson] [Source: Projects in Knowledge, Inc.] More of Today's Stories [AHA: Healthy Lifestyle Eases Heart Impact of High Genetic Risk] [AHA: No Cognitive Benefit from Heart Drugs in HOPE-3] [AHA: Long-Term Benefit in HF Patients Elusive for Novel Vasodilator] [AHA: Study Finds Celebrex Safe for Heart] [AHA: More Potent Antiplatelet Agent Not Better for PAD] CME/CE [Fine-Tuning Treatment for Ankylosing Spondylitis] CME/CE [ACAAI: Early Exposure to Peanuts May Thwart Allergy] [Xolair Tx Tied to Less Hospital Time in Young Asthmatic Kids] [NAFLD Cirrhosis Seems to Run in Families] CME/CE [CardioBrief: USPSTF Finalizes Statin Primary Prevention Guide, Debate Ensues] [Liver Cancer Rare After HCV Therapy] CME/CE [CD4+ T-Cell Counts May Predict Rituximab Response in RA] CME/CE [Readmission Penalties Are Punishing Safety-Net Hospitals] [Tweets of the Week: Honoring Vets] [Deadly Drug-Resistant Infection Spreading Among CF Patients] CME/CE [Fibrosis Risk High in Kids With Transplanted Livers] CME/CE [NSAIDs After Cataract Surgery: Do They Help at All?] CME/CE [PodMed: A Medical News Roundup From Johns Hopkins] [Cosentyx: Where Does it Fit?] CME/CE [The Mast Cell: New Target in SpA?] CME/CE [Marked Sex Difference Seen in Drug-Induced Liver Failure] [Wind Turbines Versus Bats: That's Improbable!] More news from MedPage Today® Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. © 2016 Medpage Today, LLC. All rights reserved. Use of this site constitutes acceptance of the [MedPageToday.com] [terms of use] and [privacy policy]. The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. Medpage Today is located at 345 Hudson Street, New York, NY 10014 [Remove me from this list] [Manage my e-mail settings]

Marketing emails from medpagetoday.com

View More
Sent On

02/07/2024

Sent On

02/07/2024

Sent On

02/07/2024

Sent On

01/07/2024

Sent On

01/07/2024

Sent On

01/07/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.